PET/MRI scanning session for Parkinson's (NCT07569120)
Map brain chemistry affecting thinking
- Trial ID
- NCT07569120
- Official Title
- Diving Into the in Vivo Noradrenergic System : Role of the alpha2C-adrenergic Receptors
- Goal
- Map brain chemistry affecting thinking
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Hospices Civils de Lyon
- Study Type
- INTERVENTIONAL
- Enrollment
- 165 participants
- Conditions
- Healthy Aging and Parkinson's Disease
- Interventions
- PET/MRI scanning session, Neuropsychological examination, Olfactory screening
Summary For Families
The goal is to map how the brain's noradrenergic system works in normal aging and in Parkinson's disease, doing for the first time in people a broader look at a specific receptor. The approach uses a combined positron emission tomography and magnetic resonance imaging scan with a newly developed imaging tracer that highlights a specific noradrenergic receptor called alpha2C, plus short tests of thinking, movement, and sense of smell to see how imaging matches behavior. The study is enrolling healthy adults aged 20 to 80 and people with idiopathic, levodopa-responsive Parkinson's aged 40 to 80, generally weighing 40 to 100 kilograms. People who cannot have MRI scans, who recently took medications that affect the brain, who have recent substance dependence, who are pregnant, or who had a study with radiation within the past year are not eligible.
Locations
- Hôpital Neurologique Pierre Wertheimer - Service de Neurologie, Bron, France
Frequently Asked Questions
- What is this trial testing?
- This trial is studying PET/MRI scanning session. The goal is to map how the brain's noradrenergic system works in normal aging and in Parkinson's disease, doing for the first time in people a broader look at a specific receptor. The approach uses a combined positron emission tomography and magnetic resonance imaging scan with a newly developed imaging tracer that highlights a specific noradrenergic receptor called alpha2C, plus short tests of thinking, movement, and sense of smell to see how imaging matches behavior. The study is enrolling healthy adults aged 20 to 80 and people with idiopathic, levodopa-responsive Parkinson's aged 40 to 80, generally weighing 40 to 100 kilograms. People who cannot have MRI scans, who recently took medications that affect the brain, who have recent substance dependence, who are pregnant, or who had a study with radiation within the past year are not eligible.
- Who can participate?
- Participants must be between 20 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 3 years and 2 months.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- There is no placebo group. Everyone receives an active treatment; the study compares one treatment against another.
- What procedures are involved in this trial?
- Based on the protocol, this trial involves: PET scan (minimally invasive); MRI scan (non-invasive); Thinking & memory tests (non-invasive). Confirm the full schedule with the study coordinator.